Evaluation of Children with Myelodysplastic Syndrome: Importance of Extramedullary Disease as a Presenting Symptom

References

• Tuncer M A, Pagliuca A, Hiçsönmez G, Yetgin S, Özsoylu SL, Mufti GJ. Primary myelodysplastic syndrome in children: the clinical experience in 33 cases. The British Journal of Haematology 1992; 82: 347–353
   PubMed Web of Science ®Google Scholar
• Passmore S J, Hann I M, Stiller C A, Ramani P, Swansbury G J, Gibbons B, Reeves B R, Chessells JM. Pediatric myelodysplasia: a study of 68 children and a new prognostic system. Blood 1995; 85: 1742–1750
   PubMed Web of Science ®Google Scholar
• Bader-Mennier B O, Mielot F, Tchernia G, Buisine J, Delsol G. Myelodysplastic syndromes in childhood: report of 49 patients from a French multicentre study. The British Journal of Haematology 1996; 92: 344–350
   PubMed Web of Science ®Google Scholar
• Niemeyer C M, Arico M, Basso G, Rajnoldi A, Biondi A, Cantu Creutzig U, Haas O, Harbott J, Hasle H, Kerndrup G, Locatel]i F, Mann G, Stollmann-Gibbels B, van't Veer-Korthof E T, van Wering E, Zimmermann M. Chronic myelomonocytic Leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic syndromes in Childhood (EWOG-MDS). Blood 1997; 89: 3534–3543
   PubMed Web of Science ®Google Scholar
• Hasle H, Wadsworth L D, Massing B G, McBride M, Schultz KR. A population based study of childhood myelodysplastic syndrome in British. The British Journal of Haematology, ColombiaCanada 1999; 106: 1027–1032
   Google Scholar
• Luna-Fineman S, Shannon K M, Lange BJ. Childhood monosomy: epidemiology, biology and mechanistic implications. Blood 1995; 85: 1985–1999
   PubMed Web of Science ®Google Scholar
• Haas O, Gadner H. Pathogenesis, biology and management of myelodysplastic syndromes in children. Seminars in Hematology 1996; 33: 225–235
   PubMed Web of Science ®Google Scholar
• De Silva M AP, Moriarity A, Schultz S, Tricot G. Extramedullary disease in myelodysplastic syndromes. American Journal of Medicine 1988; 85: 589–590
   PubMed Web of Science ®Google Scholar
• Enright H, Jacob H S, Vercellotti G, Howe R, Belzer M, Miller W. Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy. The British Journal of Haematology 1995; 91: 403–408
   PubMed Web of Science ®Google Scholar
• Byrd J C, Edengield W J, Dow N S, Aylesworth C, Dawson N. Extramedullary myeloid cell tumors in myelodysplastic syndromes: not a true indication of impending acute myeloid leukemia. Leukemia & Lymphoma 1996; 21: 153–159
   PubMed Web of Science ®Google Scholar
• Hiçsönmez G, Tuncer M A, Şayll T, Çetin M, Özbek N, Mufti GJ. High-dose methylprednisolone, low-dose cytosine arabinoside, and mitoxantrone in children with myelodysplastic syndromes. Hematologic Pathology 1995; 9: 185–193
   PubMedGoogle Scholar
• Hiçsönmez G, Çetin M, Tunç B, Tuncer A M, Gümrük F, Yenicesu I. Dramatic resolution of pleural effusion in children with chronic myelomonocytic leukemia following short-course high-dose methylprednisolone. Leukemia & Lymphoma 1998; 29: 617–623
   PubMed Web of Science ®Google Scholar
• Morosetti R, Koeffler HP. Differentiation therapy in myelodysplastic syndromes. Seminars in Hematology 1996; 33: 236–245
   PubMed Web of Science ®Google Scholar
• Mufti G J, Oscier D G, Hamblin T J, Bell AJ. Low doses of cytarabine in the treatment of myelodysplastic syndrome and acute myeloid leukemia. New England Journal of Medicine 1983; 309: 1653–1654
   PubMed Web of Science ®Google Scholar
• Koeffler H P, Heitjan D, Mertelsmann R, Kolitz J E, Schulman P, Itri L, Gunter P, Besa E. Randomized study of 13-cis retinoic acid versus placebo in the myelodysplastic disorders. Blood 1988; 71: 703–708
   PubMed Web of Science ®Google Scholar
• Motomura S, Kanamori H, Maruba A, Kodama F, Ohkubo T. The effect of 1-hydroxy vitamin D3 for prolongation of leukemic transformation-free survival in myelodysplastic syndromes. American Journal of Hematology 1991; 38: 67–68
   PubMed Web of Science ®Google Scholar
• Hiçsönmez G, Tuncer A M, Güler E, Tan E, Tekelioĝlu M. The potential role of high-dose methylprednisolone on the maturation of leukemic cells in children with acute promyelocytic leukemia (APL). Experimental Hematology 1993; 21: 599–601
   PubMed Web of Science ®Google Scholar
• Hiçsönmez G, Özsoylu Ş, Tuncer MA. Differentiation of myeloid leukemic cells induced by high-dose methylprednisolone in patients with acute myeloblastic leukemia and its therapeutic potential. Leukemia Research 1991; 15: 537–541
   PubMed Web of Science ®Google Scholar
• Hiçsönmez G, Özsoylu Ş, Tuncer A M, Ertürk G, Özbek N, Karadeniz N. Direct morphologic evidence of high-dose methylprednisolone induced maturation of leukemic cells in children with acute nonlymphoblastic leukemia. Experimental Hematology 1991; 19: 232–233
   PubMed Web of Science ®Google Scholar
• Hiçsönmez G, Tuncer M, Toksoy H B, Yenicesu I, Çetin M. Differentiation of leukemic cells induced by short-course high-dose methylprednisolone in children with different subtypes of acute myeloblastic leukemia. Leukemia & Lymphoma 1999; 33: 573–580
   PubMed Web of Science ®Google Scholar
• Bennett J M, Catovsky D, Daniel M T, Flandrin G, Galton D A, Gralnick H R, Sultan C. Proposals for the classification of the myelodysplastic syndromes. The British Journal of Haematology 1982; 51: 189–199
   PubMed Web of Science ®Google Scholar
• Arico M, Biondi A, Pui CH. Juvenile myelomonocytic leukemia. Blood 1997; 90: 479–488
   PubMed Web of Science ®Google Scholar
• Çetin M, Hiçsönmez G, Göĝüŝ S. Myelodysplastic syndrome associated with Griscelli syndrome. Leukemia Research 1998; 22: 859–862
   PubMed Web of Science ®Google Scholar
• Aktaŝ D, Koç A, Boduroĝlu K, Hiçsönmez G, Tunçbilek E. Myelodysplastic syndrome associated with monosomy 7 in a child with Bloom syndrome. Cancer Genetics and Cytogenetics 2000; 116: 44–46
   PubMed Web of Science ®Google Scholar
• Gümrük F, Tuncer A M, Hiçsönmez G. Pyoderma gangrenosum in a child with myelodysplastic syndrome. Journal of Pediatric Hematology and Oncology 2000; 22: 362–364
   PubMed Web of Science ®Google Scholar
• Hamblin T. Clinical features of MDS. Leukemia Research 1992; 16: 89–93
   PubMed Web of Science ®Google Scholar
• Enright H, Jacob H S, Vercellotti G, Howe R, Belzer M, Miller W. Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes:response to immunusuppressive therapy. The British Journal of Haematology 1995; 91: 403–408
   PubMed Web of Science ®Google Scholar
• Mufti G J, Oscier D G, Hamblin T J, Nightingale A, Darlow S. Serous effusions in monocytic leukemias. The British Journal of Haematology 1984; 58: 547–552
   PubMed Web of Science ®Google Scholar
• Kressler E J, Haas O A, Konig M, Mann G, Mayer H, Peters C, Gadner H, Panzer-Grumayer ER. Extramedullary relapse despite graft-versus leukemia effect after bone marrow transplantation in a girl with juvenile myelomonocytic leukemia. Leukemia & Lymphoma 1999; 33: 557–560
   Web of Science ®Google Scholar
• Hasle H, Kendrup G, Yssing M, Clausen N, Ostergaard E, Jacobsen N, Jacobsen BB. Intensive chemotherapy in childhood myelodysplastic syndrome. A comparison with results in acute myeloid leukemia. Leukemia 1996; 10: 1269–1273
   PubMed Web of Science ®Google Scholar
• Matsushima T, Murakami H, Kim K, Uchiumi H, Murata N, Tamura J, Sawamura M, Karasawa M, Naruse T, Tsuchiya J. Steroid-responsive pulmonary disorders associated with myelodysplastic syndromes with der(lq;7p) chromosomal abnormality. American Journal of Hematology 1995; 50: 110–115
   PubMed Web of Science ®Google Scholar
• Schiefke I, Halm U, Paasch U, Ponish W, Berr F, Mossner J. Pyoderma gangrenosum and portal vein thrombosis in a 33-year-old female patient. Dtsch Med Wochenschr 1999; 124: 142–145
   PubMed Web of Science ®Google Scholar
• Gürgey A, Hiçsönmez G, Parlak H, Balta G, Celiker A. Prothrombin gene 20210 G-A mutation in Turkish patients with thrombosis. American Journal of Hematology 1998; 59: 179–180
   PubMed Web of Science ®Google Scholar
• Hebbar M, Brouillard M, Wattel E, Decoulx M, Hatron P Y, Devulder B, Fenaux P. Association of myelodysplastic syndrome and relapsing polychondritis: further evidence. Leukemia 1995; 9: 1995, 731–733
   Web of Science ®Google Scholar
• Suzuki Y, Kuroda K, Kojima T, Fujita M, Iseki T, Shinkai H. Unusual cutaneous manifestations of myelodysplastic syndrome. The British Journal of Dermatology 1995; 133: 483–486
   PubMed Web of Science ®Google Scholar
• Chan G C, Wang W C, Raimondi S C, Behm F G, Krance R A, Chen G, Freiberg A, Ingram L, Butler D, Head DR. Myelodysplastic syndrome in children: differentiation from acute myeloid leukemia with a low blast count. Leukemia 1997; 11: 206–211
   PubMed Web of Science ®Google Scholar
• Creutzig U, Bender-Götze C, Zimmermann M, Stoll-mann-Gibbels B, Körholz D, Niemeyer C. The role of intensive AML-specific therapy in treatment of children with RAEB and RAEB-t. Leukemia 1988; 12: 652–659
   Web of Science ®Google Scholar
• Huang M E, Ye Y C, Chen SR., Chai J R, Lu J X, Zhoa L, Gu L J, Wang ZY. Use of all- trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567–572
   PubMed Web of Science ®Google Scholar
• Hiçsönmez G, Erdemli E, Tekelioĝlu M, Tuncer AM, Ozbek N, Cetin M, Cotter TG. Morphologic evidence of apoptosis in childhood acute myeloblastic leukemia treated with high-dose methylprednisolone. Leukemia & Lymphoma 1996; 22: 91–96
   PubMed Web of Science ®Google Scholar
• Miyoshi H, Ohki M, Nakagawa T, Honma Y. Glucocorticoid induce apoptosis in acute myeloid leukemia cell lines with a t(8;21) chromosome translocation. Leukemia Research 1997; 21: 45–50
   PubMed Web of Science ®Google Scholar
• Özbek N, Erdemli E, Hiçsönmez G, Okur H, Tekelioĝlu M. Effects of methylprednisolone on human myeloid leukemic cells in vitro. American Journal of Hematology 1999; 60: 255–259
   PubMed Web of Science ®Google Scholar
• Hiçsönmez G, Özsoylu Ş, Gürgey A, Zamani V, Irken G. High-dose methylprednisolone for remission induction in children with acute non lymphoblastic leukemia. European Journal of Haematology 1989; 42: 498–500
   PubMed Web of Science ®Google Scholar
• Hiçsönmez G, Karadeniz N, Zamani V P, Tuncer A M, Gümrük F, Erturk G, Gürgey A, Özsoylu S. High remission rate in acute myeloblastic leukemia in children treated with high- dose methylprednisolone. European Journal of Haematology 1992; 48: 215–220
   PubMed Web of Science ®Google Scholar
• Hiçsönmez G, Onat N, Albayrak D, Yetgin S, Özsoylu S. Acceleration of leukocyte recovery by administration of short-course high-dose methylprednisolone in children with acute lymphoblastic leukemia. Pediatric Hematology and Oncology 1991; 8: 193–197
   PubMed Web of Science ®Google Scholar
• Çetin M, Hiçsönmez G, Tuncer A M, Kansu E, Canpinar H. The effect of short-course high-dose corticosteroid therapy on peripheral blood CD34+ progenitor cells in children with acute leukemia. Experimental Hematology 1996; 24: 1191–1194
   PubMed Web of Science ®Google Scholar
• Tuncer A M, Hiçsönmez G, Gümrük F, Şayll T, Güler E, Çetin M, Okur H. Serum TNF-alpha, gamma-INF, G-CSF and GM-CSF levels in neutropenic children with acute leukemia treated with short-course, high-dose methylprednisolone. Leukemia Research 1996; 20: 265–269
   PubMed Web of Science ®Google Scholar
• Bagby G C, Gabourel J D, Linman JW. Glucocorticoid therapy in the preleukemic syndrome (hemopoietic dysplasia): identification of responsive patients using in- vitro techniques. Annals of Internal Medicine 1980; 92: 55–58
   PubMed Web of Science ®Google Scholar
• Prystowsky J H, Johnson B LJ, Bolwell B J, Lazarus GS. Treatment of cutaneous granulocytic sarcoma in a patient with myelodysplasia. American Journal of Medicine 1989; 86: 477–480
   PubMed Web of Science ®Google Scholar
• Motoji T, Teramura M, Takahashi M, Oshimi K, Okada M, Kusakabe K, Mizoguchi H. Successful treatment of refractory anemia with high-dose methylprednisolone. American Journal of Haematology 1990; 33: 8–12
   PubMed Web of Science ®Google Scholar
• George S W, Newman ED. Seronegative inflammatory arthritis in the myelodysplastic syndromes. Seminers in Arthritis Rheumatology 1992; 21: 345–354
   PubMed Web of Science ®Google Scholar
• Imai Y, Fukuoka T, Nakatani A, Ohsaka A, Takahashi A. Sustained trilineage recovery and disappearance of abnormal chromosome clone in a patient with myelodysplastic syndrome following combination therapy with cytokines (granulocyte colony-stimulating factor and erythropoietin) and high-dose methylprednisolone. The British Journal of Haematology 1996; 93: 146–150
   PubMed Web of Science ®Google Scholar
• Yenicesu I, Hiçsönmez G, Tuncer AM. Effect of short-course high-dose methylprednisolone treatment on serum IL-2 levels in children with myelodysplastic syndromes: a pilot study. Leukemia Research 1997; 21: 789–791
   PubMed Web of Science ®Google Scholar